Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gain Therapeutics Inc (GANX)

Gain Therapeutics Inc (GANX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 88,847
  • Shares Outstanding, K 38,462
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,410 K
  • EBIT $ -18 M
  • EBITDA $ -18 M
  • 60-Month Beta 0.06
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 14.84

Options Overview Details

View History
  • Implied Volatility 160.53% (-34.62%)
  • Historical Volatility 205.49%
  • IV Percentile 21%
  • IV Rank 10.86%
  • IV High 1,194.61% on 03/18/25
  • IV Low 34.58% on 09/04/25
  • Expected Move (DTE 4) 0.98 (42.32%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 621
  • Volume Avg (30-Day) 1,566
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 20,071
  • Open Int (30-Day) 22,178
  • Expected Range 1.33 to 3.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.14
  • Number of Estimates 3
  • High Estimate -0.13
  • Low Estimate -0.15
  • Prior Year -0.11
  • Growth Rate Est. (year over year) -27.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.14 +7.75%
on 12/18/25
4.28 -46.12%
on 12/15/25
-1.83 (-44.30%)
since 12/12/25
3-Month
1.66 +38.91%
on 11/04/25
4.34 -46.87%
on 12/11/25
+0.34 (+17.05%)
since 10/10/25
52-Week
1.41 +63.54%
on 08/01/25
4.34 -46.87%
on 12/11/25
+0.01 (+0.26%)
since 01/10/25

Most Recent Stories

More News
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week

BETHESDA, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development...

GANX : 2.22 (-3.90%)
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287

BETHESDA, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development...

GANX : 2.22 (-3.90%)
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease

BETHESDA, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development...

GANX : 2.22 (-3.90%)
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease

Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), a prespecified endpoint The reduction in GluSph in CSF, a first-ever...

GANX : 2.22 (-3.90%)
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025

GT-02287 reduces mitochondrial stress and enhances neuronal survival in MPP+ treated rat dopaminergic neurons GT-02287 decreases staining for MIRO1, suggesting improved mitochondrial health in α-synuclein-induced...

GANX : 2.22 (-3.90%)
Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update

Presented initial data from Phase 1b study suggesting GT-02287 has a disease-slowing effect consistent with the preclinical models in vivo and the proposed mechanism of action Completed enrollment...

GANX : 2.22 (-3.90%)
Gain Therapeutics to Present at Neuroscience 2025

BETHESDA, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development...

GANX : 2.22 (-3.90%)
Gain Therapeutics to Attend the 2025 Maxim Growth Summit

BETHESDA, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development...

GANX : 2.22 (-3.90%)
Analysts Are Bullish on These Healthcare Stocks: Candel Therapeutics (CADL), Gain Therapeutics (GANX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Candel Therapeutics (CADL – Research Report) and Gain Therapeutics (GANX – Research Report) with bullish...

GANX : 2.22 (-3.90%)
CADL : 5.70 (-0.18%)
Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (GANX) and MannKind (MNKD)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gain Therapeutics (GANX – Research Report) and MannKind (MNKD – Research Report) with bullish sentiments.Elevate...

GANX : 2.22 (-3.90%)
MNKD : 5.83 (-0.34%)

Business Summary

Gain Therapeutics Inc. is redefining drug discovery with its See-Tx(TM) target identification platform. It involved in identifying and optimizing allosteric binding sites which have never before been targeted. The company is unlocking new treatment options for difficult-to-treat disorders characterized...

See More

Key Turning Points

3rd Resistance Point 2.71
2nd Resistance Point 2.61
1st Resistance Point 2.46
Last Price 2.22
1st Support Level 2.21
2nd Support Level 2.11
3rd Support Level 1.96

See More

52-Week High 4.34
Fibonacci 61.8% 3.22
Fibonacci 50% 2.88
Fibonacci 38.2% 2.53
Last Price 2.22
52-Week Low 1.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar